364 related articles for article (PubMed ID: 11650075)
1. The case for per patient payments.
Lewis JP
IRB; 1988; 10(5):9. PubMed ID: 11650075
[No Abstract] [Full Text] [Related]
2. Why I oppose drug company payment of physician/investigators on a per patient/subject basis.
Roizen R
IRB; 1988; 10(1):9-10. PubMed ID: 11658990
[No Abstract] [Full Text] [Related]
3. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
4. Dilemmas in paying for clinical research: the view from the IRB.
Lind SE
IRB; 1987; 9(2):1-5. PubMed ID: 11649900
[No Abstract] [Full Text] [Related]
5. Drug trials hide conflicts for doctors.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():1, 34. PubMed ID: 11648114
[No Abstract] [Full Text] [Related]
6. Playing roulette with experimental drugs.
Budiansky S
US News World Rep; 1987 Jul; 103(2):58-9. PubMed ID: 11658841
[No Abstract] [Full Text] [Related]
7. Ethical responsibilities of physicians in their dealings with pharmaceutical companies.
Royal College of Physicians and Surgeons of Canada. Biomedical Ethics Committee
Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):45-8. PubMed ID: 11650305
[No Abstract] [Full Text] [Related]
8. FDA's new rule on treatment use and sale of investigational new drugs.
Levine RJ
IRB; 1987; 9(4):1-4. PubMed ID: 11649946
[No Abstract] [Full Text] [Related]
9. Testing new drugs: joining a study can be rewarding -- but risky How to find -- and survive -- a clinical trial.
Consum Rep; 1998 Dec; 63(12):64-5. PubMed ID: 11660639
[No Abstract] [Full Text] [Related]
10. Perspectives of protocol reviewers.
Moline ML; Aisen MW
J Calif Alliance Ment Ill; 1994; 5(1):59-60. PubMed ID: 11653327
[No Abstract] [Full Text] [Related]
11. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
Kobasic DM
J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
[No Abstract] [Full Text] [Related]
12. Ethical considerations in informed consent for potential future use of human tissue samples.
Adams M; Prentice ED; Oki GS
IRB; 1996; 18(2):6-7. PubMed ID: 11654756
[No Abstract] [Full Text] [Related]
13. In search of funding: the clinical investigator and the drug company; Commentary: why researchers need not be demoralized.
Siris ES; Burrell CD
IRB; 1983; 5(6):1-5. PubMed ID: 11649526
[No Abstract] [Full Text] [Related]
14. Payments to doctors and the responsibilities of ethics committees.
Diamond AL; Robinson K; Cousins J
Br Med J (Clin Res Ed); 1984 Jan; 288(6413):322-3. PubMed ID: 11658728
[No Abstract] [Full Text] [Related]
15. Money is putting people at risk in biomedical research.
Andrews LB
Chron High Educ; 2000 Mar; 46(27):B1, B4-5. PubMed ID: 11657699
[No Abstract] [Full Text] [Related]
16. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
17. The paradoxical case of payment as benefit to research subjects.
Macklin R
IRB; 1989; 11(6):1-3. PubMed ID: 11650284
[No Abstract] [Full Text] [Related]
18. Policies and quality assurance in the pharmaceutical industry.
Shamoo AE
Account Res; 1991; 1(4):273-84. PubMed ID: 11651459
[No Abstract] [Full Text] [Related]
19. Conflict of interest in human research ethics.
Jones DJ
NCBHR Commun; 1995; 6(2):5-10. PubMed ID: 11654611
[No Abstract] [Full Text] [Related]
20. IRBs and pharmaceutical company funding of research.
Jellinek MS; Levine RJ
IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
